ACCESS Newswire·May 8, 2026, 8:00 AM ET

Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam

ENSC

Ensysce Biosciences, Inc. (NASDAQ: ENSC) announced that CEO Dr. Lynn Kirkpatrick presented as an invited speaker & participated on a panel at the first Pain Therapeutics Summit Europe held in Amsterdam May 7-8, 2026.
Dr. Kirkpatrick's presentation titled "Chemical Control, Clinical Confidence: Rethinking Opioids" outlined a paradigm shift toward chemically engineered drugs with built-in safety controls to redefine the opioid benefit-risk equation.
The presentation highlighted Ensysce's proprietary platforms: TAAP™ (Trypsin-Activated Abuse Protection) designed to reduce non-oral misuse, & MPAR® (Multi-Pill Abuse Resistance) engineered to create a ceiling on plasma levels during overdose events.
Dr. Kirkpatrick stated the company's approach embeds control directly into the drug to preserve analgesic efficacy while actively reducing abuse & overdose risks associated with traditional opioids.
During the panel discussion "Safer Analgesics Without Losing Efficacy," experts discussed clinical developments for more effective pain products with improved safety profiles & reviewed Ensysce's clinical programs.
Ensysce Biosciences is a clinical-stage company developing tamper-proof opioid treatments using its TAAP™ & MPAR® platforms to minimize abuse & overdose risk for severe pain patients.
The press release includes forward-looking statements regarding the potential success of clinical programs, regulatory approvals, & commercialization, noting inherent uncertainties & risks including potential NASDAQ delisting.